http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Mar 2026 08:02:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Achieve+Life+Sciences+presents+smoking+cessation+data+at+SRNT+meeting/26107491.html <p>Achieve Life Sciences Inc. (NASDAQ: ACHV) presented data at the Society for Research on Nicotine & Tobacco Annual Meeting showing that cytisinicline helped participants quit smoking regardless of their prior treatment history or number of previous quit attempts.</p><p>The analysis pooled data from the ORCA-2 and ORCA-3 Phase 3 trials, examining outcomes in 1,602 participants with varying histories of prior quit medications, including varenicline, bupropion, and nicotine replacement therapy. The study also examined participants who had made four or fewer previous quit attempts versus those with more than four attempts.</p><p>"In this analysis, cytisinicline helped people to quit smoking, even those individuals http://www.streetinsider.com/Corporate+News/Achieve+Life+Sciences+presents+smoking+cessation+data+at+SRNT+meeting/26107491.html Wed, 04 Mar 2026 08:02:00 -0500 ACHV http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Press+Releases/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027 http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html <p align="center"><em>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts </em></p> <p align="center"><em>Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use</em></p> <p align="left">SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced new http://www.streetinsider.com/Globe+Newswire/Achieve+Life+Sciences+Presents+Data+at+SRNT+Demonstrating+Successful+Cessation+in+Smokers+with+Extensive+Prior+Treatment+Exposure%3B+and+on+Participant+Experience+in+the+ORCA-OL+Study/26107469.html Wed, 04 Mar 2026 08:00:00 -0500 A.06822034 A.14320728 A.17568957 A.21849991 A.35954321 A.38925042 A.40221050 ACHV O.00644671 O.03285412 O.04889877 O.20026344 O.20042365 O.20250741 O.20331252 O.20737027